Sp1 and the 'hallmarks of cancer'

FEBS Journal

Volumn 282, Issue 2, 2015, Pages 224-258

  Beishline, Kate ^a   Azizkhan Clifford, Jane ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

cancer; oncogene; Sp1; transcription; tumor suppressor

Indexed keywords

SP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SP1;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROTEIN PROCESSING; TATA BOX; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SP1 TRANSCRIPTION FACTOR; TATA BOX; TRANSCRIPTION, GENETIC;

EID: 84926081071     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13148     Document Type: Review

References (378)

1. Dynan WS, &, Tjian R, (1983) The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell 35, 79-87.
2. Dynan WS, &, Tjian R, (1983) Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II. Cell 32, 669-680.
3. Black AR, Black JD, &, Azizkhan-Clifford J, (2001) Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188, 143-160.
4. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, Piccolboni A, Sementchenko V, Cheng J, Williams AJ, et al,. (2004) Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116, 499-509.
5. Oleaga C, Welten S, Belloc A, Sole A, Rodriguez L, Mencia N, Selga E, Tapias A, Noe V, &, Ciudad CJ, (2012) Identification of novel Sp1 targets involved in proliferation and cancer by functional genomics. Biochem Pharmacol 84, 1581-1591.
6. Gilmour J, Assi SA, Jaegle U, Kulu D, van de Werken H, Clarke D, Westhead DR, Philipsen S, &, Bonifer C, (2014) A crucial role for the ubiquitously expressed transcription factor Sp1 at early stages of hematopoietic specification. Development 141, 2391-2401.
7. Bouwman P, &, Philipsen S, (2002) Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 195, 27-38.
8. Kaczynski J, Cook T, &, Urrutia R, (2003) Sp1- and Kruppel-like transcription factors. Genome Biol 4, 206.
9. Thiesen HJ, &, Bach C, (1990) Target Detection Assay (TDA): a versatile procedure to determine DNA binding sites as demonstrated on SP1 protein. Nucleic Acids Res 18, 3203-3209.
10. Kingsley C, &, Winoto A, (1992) Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol Cell Biol 12, 4251-4261.
11. Hagen G, Dennig J, Preiss A, Beato M, &, Suske G, (1995) Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3. J Biol Chem 270, 24989-24994.
12. Crossley M, Whitelaw E, Perkins A, Williams G, Fujiwara Y, &, Orkin SH, (1996) Isolation and characterization of the cDNA encoding BKLF/TEF-2, a major CACCC-box-binding protein in erythroid cells and selected other cells. Mol Cell Biol 16, 1695-1705.
13. Matsumoto N, Laub F, Aldabe R, Zhang W, Ramirez F, Yoshida T, &, Terada M, (1998) Cloning the cDNA for a new human zinc finger protein defines a group of closely related Kruppel-like transcription factors. J Biol Chem 273, 28229-28237.
14. Shields JM, &, Yang VW, (1998) Identification of the DNA sequence that interacts with the gut-enriched Kruppel-like factor. Nucleic Acids Res 26, 796-802.
15. Nagaoka M, Shiraishi Y, &, Sugiura Y, (2001) Selected base sequence outside the target binding site of zinc finger protein Sp1. Nucleic Acids Res 29, 4920-4929.
16. Kadonaga JT, Jones KA, &, Tjian R, (1986) Promoter-specific activation of RNA polymerase II transcription by Sp1. Trends Biochem Sci 11, 20-23.
17. Kriwacki RW, Schultz SC, Steitz TA, &, Caradonna JP, (1992) Sequence-specific recognition of DNA by zinc-finger peptides derived from the transcription factor Sp1. Proc Natl Acad Sci USA 89, 9759-9763.
18. Thiesen HJ, &, Schroder B, (1991) Amino acid substitutions in the SP1 zinc finger domain alter the DNA binding affinity to cognate SP1 target site. Biochem Biophys Res Commun 175, 333-338.
19. Ito T, Azumano M, Uwatoko C, Itoh K, &, Kuwahara J, (2009) Role of zinc finger structure in nuclear localization of transcription factor Sp1. Biochem Biophys Res Commun 380, 28-32.
20. Ito T, Kitamura H, Uwatoko C, Azumano M, Itoh K, &, Kuwahara J, (2010) Interaction of Sp1 zinc finger with transport factor in the nuclear localization of transcription factor Sp1. Biochem Biophys Res Commun 403, 161-166.
21. Su W, Jackson S, Tjian R, &, Echols H, (1991) DNA looping between sites for transcriptional activation: self-association of DNA-bound Sp1. Genes Dev 5, 820-826.
22. Mastrangelo IA, Courey AJ, Wall JS, Jackson SP, &, Hough PV, (1991) DNA looping and Sp1 multimer links: a mechanism for transcriptional synergism and enhancement. Proc Natl Acad Sci USA 88, 5670-5674.
23. Dennig J, Beato M, &, Suske G, (1996) An inhibitor domain in Sp3 regulates its glutamine-rich activation domains. EMBO J 15, 5659-5667.
24. Hagen G, Muller S, Beato M, &, Suske G, (1994) Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J 13, 3843-3851.
25. Majello B, De Luca P, Hagen G, Suske G, &, Lania L, (1994) Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1. Nucleic Acids Res 22, 4914-4921.
26. Hammill D, Jain N, Armstrong S, &, Mueller CR, (2005) The D-domain of Sp3 modulates its protein levels and activation of the p21(CIP1/WAF1) promoter. Biochem Biophys Res Commun 335, 377-384.
27. Wierstra I, (2008) Sp1: emerging roles-beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 372, 1-13.
28. Williams AO, Isaacs RJ, &, Stowell KM, (2007) Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions. BMC Mol Biol 8, 36.
29. Li L, &, Davie JR, (2010) The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 192, 275-283.
30. Marin M, Karis A, Visser P, Grosveld F, &, Philipsen S, (1997) Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell 89, 619-628.
31. Kruger I, Vollmer M, Simmons DG, Elsasser HP, Philipsen S, &, Suske G, (2007) Sp1/Sp3 compound heterozygous mice are not viable: impaired erythropoiesis and severe placental defects. Dev Dyn 236, 2235-2244.
32. Gollner H, Dani C, Phillips B, Philipsen S, &, Suske G, (2001) Impaired ossification in mice lacking the transcription factor Sp3. Mech Dev 106, 77-83.
33. Ma W, Horvath GC, Kistler MK, &, Kistler WS, (2008) Expression patterns of SP1 and SP3 during mouse spermatogenesis: SP1 down-regulation correlates with two successive promoter changes and translationally compromised transcripts. Biol Reprod 79, 289-300.
34. Wimmer EA, Frommer G, Purnell BA, &, Jackle H, (1996) buttonhead and D-Sp1: a novel Drosophila gene pair. Mech Dev 59, 53-62.
35. Athanikar JN, Sanchez HB, &, Osborne TF, (1997) Promoter selective transcriptional synergy mediated by sterol regulatory element binding protein and Sp1: a critical role for the Btd domain of Sp1. Mol Cell Biol 17, 5193-5200.
36. Kadonaga JT, Courey AJ, Ladika J, &, Tjian R, (1988) Distinct regions of Sp1 modulate DNA binding and transcriptional activation. Science 242, 1566-1570.
37. Courey AJ, &, Tjian R, (1988) Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell 55, 887-898.
38. Oka S, Shiraishi Y, Yoshida T, Ohkubo T, Sugiura Y, &, Kobayashi Y, (2004) NMR structure of transcription factor Sp1 DNA binding domain. Biochemistry 43, 16027-16035.
39. Narayan VA, Kriwacki RW, &, Caradonna JP, (1997) Structures of zinc finger domains from transcription factor Sp1. Insights into sequence-specific protein-DNA recognition. J Biol Chem 272, 7801-7809.
40. Infantino V, Convertini P, Iacobazzi F, Pisano I, Scarcia P, &, Iacobazzi V, (2011) Identification of a novel Sp1 splice variant as a strong transcriptional activator. Biochem Biophys Res Commun 412, 86-91.
41. Jackson SP, MacDonald JJ, Lees-Miller S, &, Tjian R, (1990) GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell 63, 155-165.
42. Jackson SP, &, Tjian R, (1988) O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. Cell 55, 125-133.
43. Rigbolt KT, Prokhorova TA, Akimov V, Henningsen J, Johansen PT, Kratchmarova I, Kassem M, Mann M, Olsen JV, &, Blagoev B, (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3.
44. Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, et al,. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3.
45. Spengler ML, Guo LW, &, Brattain MG, (2008) Phosphorylation mediates Sp1 coupled activities of proteolytic processing, desumoylation and degradation. Cell Cycle 7, 623-630.
46. Spengler ML, &, Brattain MG, (2006) Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription. J Biol Chem 281, 5567-5574.
47. Chuang JY, Wang YT, Yeh SH, Liu YW, Chang WC, &, Hung JJ, (2008) Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis. Mol Biol Cell 19, 1139-1151.
48. Wang YT, Yang WB, Chang WC, &, Hung JJ, (2011) Interplay of posttranslational modifications in Sp1 mediates Sp1 stability during cell cycle progression. J Mol Biol 414, 1-14.
49. Iwahori S, Yasui Y, Kudoh A, Sato Y, Nakayama S, Murata T, Isomura H, &, Tsurumi T, (2008) Identification of phosphorylation sites on transcription factor Sp1 in response to DNA damage and its accumulation at damaged sites. Cell Signal 20, 1795-1803.
50. Vicart A, Lefebvre T, Imbert J, Fernandez A, &, Kahn-Perles B, (2006) Increased chromatin association of Sp1 in interphase cells by PP2A-mediated dephosphorylations. J Mol Biol 364, 897-908.
51. Kim HS, &, Lim IK, (2009) Phosphorylated extracellular signal-regulated protein kinases 1 and 2 phosphorylate Sp1 on serine 59 and regulate cellular senescence via transcription of p21Sdi1/Cip1/Waf1. J Biol Chem 284, 15475-15486.
52. Fojas de Borja P, Collins NK, Du P, Azizkhan-Clifford J, &, Mudryj M, (2001) Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. EMBO J 20, 5737-5747.
53. Beausoleil SA, Villen J, Gerber SA, Rush J, &, Gygi SP, (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-1292.
54. Olofsson BA, Kelly CM, Kim J, Hornsby SM, &, Azizkhan-Clifford J, (2007) Phosphorylation of Sp1 in response to DNA damage by ataxia telangiectasia-mutated kinase. Mol Cancer Res 5, 1319-1330.
55. Iwahori S, Shirata N, Kawaguchi Y, Weller SK, Sato Y, Kudoh A, Nakayama S, Isomura H, &, Tsurumi T, (2007) Enhanced phosphorylation of transcription factor sp1 in response to herpes simplex virus type 1 infection is dependent on the ataxia telangiectasia-mutated protein. J Virol 81, 9653-9664.
56. Chun RF, Semmes OJ, Neuveut C, &, Jeang KT, (1998) Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J Virol 72, 2615-2629.
57. Zheng XL, Matsubara S, Diao C, Hollenberg MD, &, Wong NC, (2001) Epidermal growth factor induction of apolipoprotein A-I is mediated by the Ras-MAP kinase cascade and Sp1. J Biol Chem 276, 13822-13829.
58. Bonello MR, &, Khachigian LM, (2004) Fibroblast growth factor-2 represses platelet-derived growth factor receptor-alpha (PDGFR-alpha) transcription via ERK1/2-dependent Sp1 phosphorylation and an atypical cis-acting element in the proximal PDGFR-alpha promoter. J Biol Chem 279, 2377-2382.
59. Milanini-Mongiat J, Pouyssegur J, &, Pages G, (2002) Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 277, 20631-20639.
60. Hsu MC, Chang HC, &, Hung WC, (2006) HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem 281, 4718-4725.
61. Roos MD, Su K, Baker JR, &, Kudlow JE, (1997) O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. Mol Cell Biol 17, 6472-6480.
62. Yang X, Su K, Roos MD, Chang Q, Paterson AJ, &, Kudlow JE, (2001) O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci USA 98, 6611-6616.
63. Rickers A, Peters N, Badock V, Beyaert R, Vandenabeele P, Dorken B, &, Bommert K, (1999) Cleavage of transcription factor SP1 by caspases during anti-IgM-induced B-cell apoptosis. Eur J Biochem 261, 269-274.
64. Majumdar G, Harrington A, Hungerford J, Martinez-Hernandez A, Gerling IC, Raghow R, &, Solomon S, (2006) Insulin dynamically regulates calmodulin gene expression by sequential o-glycosylation and phosphorylation of sp1 and its subcellular compartmentalization in liver cells. J Biol Chem 281, 3642-3650.
65. Zhang Y, Liao M, &, Dufau ML, (2006) Phosphatidylinositol 3-kinase/protein kinase Czeta-induced phosphorylation of Sp1 and p107 repressor release have a critical role in histone deacetylase inhibitor-mediated derepression [corrected] of transcription of the luteinizing hormone receptor gene. Mol Cell Biol 26, 6748-6761.
66. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, &, Gygi SP, (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA 105, 10762-10767.
67. Armstrong SA, Barry DA, Leggett RW, &, Mueller CR, (1997) Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity. J Biol Chem 272, 13489-13495.
68. Tan NY, Midgley VC, Kavurma MM, Santiago FS, Luo X, Peden R, Fahmy RG, Berndt MC, Molloy MP, &, Khachigian LM, (2008) Angiotensin II-inducible platelet-derived growth factor-D transcription requires specific Ser/Thr residues in the second zinc finger region of Sp1. Circ Res 102, e38-e51.
69. Hung JJ, Wang YT, &, Chang WC, (2006) Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcription. Mol Cell Biol 26, 1770-1785.
70. Waby JS, Chirakkal H, Yu C, Griffiths GJ, Benson RS, Bingle CD, &, Corfe BM, (2010) Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer 9, 275.
71. Suzuki T, Kimura A, Nagai R, &, Horikoshi M, (2000) Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells 5, 29-41.
72. Kang JE, Kim MH, Lee JA, Park H, Min-Nyung L, Auh CK, &, Hur MW, (2005) Histone deacetylase-1 represses transcription by interacting with zinc-fingers and interfering with the DNA binding activity of Sp1. Cell Physiol Biochem 16, 23-30.
73. Wei S, Chuang HC, Tsai WC, Yang HC, Ho SR, Paterson AJ, Kulp SK, &, Chen CS, (2009) Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of beta-transducin repeat-containing protein. Mol Pharmacol 76, 47-57.
74. Beishline K, Kelly CM, Olofsson BA, Koduri S, Emrich J, Greenberg RA, &, Azizkhan-Clifford J, (2012) Sp1 facilitates DNA double-strand break repair through a nontranscriptional mechanism. Mol Cell Biol 32, 3790-3799.
75. Han I, &, Kudlow JE, (1997) Reduced O-glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol 17, 2550-2558.
76. Su K, Roos MD, Yang X, Han I, Paterson AJ, &, Kudlow JE, (1999) An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro. J Biol Chem 274, 15194-15202.
77. Su K, Yang X, Roos MD, Paterson AJ, &, Kudlow JE, (2000) Human Sug1/p45 is involved in the proteasome-dependent degradation of Sp1. Biochem J 348 (Pt 2), 281-289.
78. Wang YT, Chuang JY, Shen MR, Yang WB, Chang WC, &, Hung JJ, (2008) Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process. J Mol Biol 380, 869-885.
79. Emili A, Greenblatt J, &, Ingles CJ, (1994) Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. Mol Cell Biol 14, 1582-1593.
80. Torigoe T, Izumi H, Yoshida Y, Ishiguchi H, Okamoto T, Itoh H, &, Kohno K, (2003) Low pH enhances Sp1 DNA binding activity and interaction with TBP. Nucleic Acids Res 31, 4523-4530.
81. Kundu TK, Palhan VB, Wang Z, An W, Cole PA, &, Roeder RG, (2000) Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300. Mol Cell 6, 551-561.
82. Chen YJ, Wang YN, &, Chang WC, (2007) ERK2-mediated C-terminal serine phosphorylation of p300 is vital to the regulation of epidermal growth factor-induced keratin 16 gene expression. J Biol Chem 282, 27215-27228.
83. Hoey T, Weinzierl RO, Gill G, Chen JL, Dynlacht BD, &, Tjian R, (1993) Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators. Cell 72, 247-260.
84. Chen JL, Attardi LD, Verrijzer CP, Yokomori K, &, Tjian R, (1994) Assembly of recombinant TFIID reveals differential coactivator requirements for distinct transcriptional activators. Cell 79, 93-105.
85. Gill G, Pascal E, Tseng ZH, &, Tjian R, (1994) A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation. Proc Natl Acad Sci USA 91, 192-196.
86. Tanese N, Saluja D, Vassallo MF, Chen JL, &, Admon A, (1996) Molecular cloning and analysis of two subunits of the human TFIID complex: hTAFII130 and hTAFII100. Proc Natl Acad Sci USA 93, 13611-13616.
87. Saluja D, Vassallo MF, &, Tanese N, (1998) Distinct subdomains of human TAFII130 are required for interactions with glutamine-rich transcriptional activators. Mol Cell Biol 18, 5734-5743.
88. Rojo-Niersbach E, Furukawa T, &, Tanese N, (1999) Genetic dissection of hTAF(II)130 defines a hydrophobic surface required for interaction with glutamine-rich activators. J Biol Chem 274, 33778-33784.
89. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, &, Krainc D, (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238-2243.
90. Ma Z, Chang MJ, Shah R, Adamski J, Zhao X, &, Benveniste EN, (2004) Brg-1 is required for maximal transcription of the human matrix metalloproteinase-2 gene. J Biol Chem 279, 46326-46334.
91. Kadam S, McAlpine GS, Phelan ML, Kingston RE, Jones KA, &, Emerson BM, (2000) Functional selectivity of recombinant mammalian SWI/SNF subunits. Genes Dev 14, 2441-2451.
92. Kadam S, &, Emerson BM, (2003) Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. Mol Cell 11, 377-389.
93. Liu H, Kang H, Liu R, Chen X, &, Zhao K, (2002) Maximal induction of a subset of interferon target genes requires the chromatin-remodeling activity of the BAF complex. Mol Cell Biol 22, 6471-6479.
94. Xu YZ, Heravi M, Thuraisingam T, Di Marco S, Muanza T, &, Radzioch D, (2010) Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1. Mol Cancer 9, 210.
95. Chiang CM, &, Roeder RG, (1995) Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators. Science 267, 531-536.
96. De Cesare D, Fimia GM, Brancorsini S, Parvinen M, &, Sassone-Corsi P, (2003) Transcriptional control in male germ cells: general factor TFIIA participates in CREM-dependent gene activation. Mol Endocrinol 17, 2554-2565.
97. Aiello A, Pandini G, Sarfstein R, Werner H, Manfioletti G, Vigneri R, &, Belfiore A, (2010) HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. Eur J Cancer 46, 1919-1926.
98. Li AY, Lin HH, Kuo CY, Shih HM, Wang CC, Yen Y, &, Ann DK, (2011) High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis. Mol Cell Biol 31, 2605-2617.
99. Suzuki T, Muto S, Miyamoto S, Aizawa K, Horikoshi M, &, Nagai R, (2003) Functional interaction of the DNA-binding transcription factor Sp1 through its DNA-binding domain with the histone chaperone TAF-I. J Biol Chem 278, 28758-28764.
100. Esteve PO, Chin HG, &, Pradhan S, (2007) Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 282, 2615-2625.
101. Song J, Ugai H, Kanazawa I, Sun K, &, Yokoyama KK, (2001) Independent repression of a GC-rich housekeeping gene by Sp1 and MAZ involves the same cis-elements. J Biol Chem 276, 19897-19904.
102. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, &, Seiser C, (1999) Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 19, 5504-5511.
103. Zhang Y, &, Dufau ML, (2002) Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex. J Biol Chem 277, 33431-33438.
104. Chang YC, Illenye S, &, Heintz NH, (2001) Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene. Mol Cell Biol 21, 1121-1131.
105. Hou M, Wang X, Popov N, Zhang A, Zhao X, Zhou R, Zetterberg A, Bjorkholm M, Henriksson M, Gruber A, et al,. (2002) The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res 274, 25-34.
106. Ohlsson C, Kley N, Werner H, &, LeRoith D, (1998) p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 139, 1101-1107.
107. Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E, et al,. (2003) The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol 23, 2669-2679.
108. Won J, Yim J, &, Kim TK, (2002) Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J Biol Chem 277, 38230-38238.
109. Sun JM, Chen HY, Moniwa M, Litchfield DW, Seto E, &, Davie JR, (2002) The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2. J Biol Chem 277, 35783-35786.
110. Lin SY, Black AR, Kostic D, Pajovic S, Hoover CN, &, Azizkhan JC, (1996) Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction. Mol Cell Biol 16, 1668-1675.
111. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, &, Tyner AL, (2001) Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 98, 4510-4515.
112. Ichimura T, Watanabe S, Sakamoto Y, Aoto T, Fujita N, &, Nakao M, (2005) Transcriptional repression and heterochromatin formation by MBD1 and MCAF/AM family proteins. J Biol Chem 280, 13928-13935.
113. Kardassis D, Papakosta P, Pardali K, &, Moustakas A, (1999) c-Jun transactivates the promoter of the human p21(WAF1/Cip1) gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J Biol Chem 274, 29572-29581.
114. Gizard F, Robillard R, Barbier O, Quatannens B, Faucompre A, Revillion F, Peyrat JP, Staels B, &, Hum DW, (2005) TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1. Mol Cell Biol 25, 4335-4348.
115. Abramovitch S, Glaser T, Ouchi T, &, Werner H, (2003) BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett 541, 149-154.
116. Dong J, Tsai-Morris CH, &, Dufau ML, (2006) A novel estradiol/estrogen receptor alpha-dependent transcriptional mechanism controls expression of the human prolactin receptor. J Biol Chem 281, 18825-18836.
117. Tapias A, Ciudad CJ, Roninson IB, &, Noe V, (2008) Regulation of Sp1 by cell cycle related proteins. Cell Cycle 7, 2856-2867.
118. Vallian S, Chin KV, &, Chang KS, (1998) The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter. Mol Cell Biol 18, 7147-7156.
119. Johnson-Pais T, Degnin C, &, Thayer MJ, (2001) pRB induces Sp1 activity by relieving inhibition mediated by MDM2. Proc Natl Acad Sci USA 98, 2211-2216.
120. Lim K, &, Chang HI, (2009) O-GlcNAc inhibits interaction between Sp1 and Elf-1 transcription factors. Biochem Biophys Res Commun 380, 569-574.
121. Pal S, Claffey KP, Cohen HT, &, Mukhopadhyay D, (1998) Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem 273, 26277-26280.
122. Cohen HT, Zhou M, Welsh AM, Zarghamee S, Scholz H, Mukhopadhyay D, Kishida T, Zbar B, Knebelmann B, &, Sukhatme VP, (1999) An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem Biophys Res Commun 266, 43-50.
123. Rafty LA, &, Khachigian LM, (2002) von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter. J Cell Biochem 85, 490-495.
124. Lim K, &, Chang HI, (2009) O-GlcNAc modification of Sp1 inhibits the functional interaction between Sp1 and Oct1. FEBS Lett 583, 512-520.
125. Lim K, &, Chang HI, (2009) O-GlcNAcylation of Sp1 interrupts Sp1 interaction with NF-Y. Biochem Biophys Res Commun 382, 593-597.
126. Di Padova M, Bruno T, De Nicola F, Iezzi S, D'Angelo C, Gallo R, Nicosia D, Corbi N, Biroccio A, Floridi A, et al,. (2003) Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter. J Biol Chem 278, 36496-36504.
127. Zhang X, &, Liu Y, (2003) Suppression of HGF receptor gene expression by oxidative stress is mediated through the interplay between Sp1 and Egr-1. Am J Physiol Renal Physiol 284, F1216-F1225.
128. Trinh BQ, Barengo N, &, Naora H, (2011) Homeodomain protein DLX4 counteracts key transcriptional control mechanisms of the TGF-beta cytostatic program and blocks the antiproliferative effect of TGF-beta. Oncogene 30, 2718-2729.
129. Koshiji M, To KK, Hammer S, Kumamoto K, Harris AL, Modrich P, &, Huang LE, (2005) HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 17, 793-803.
130. Gueven N, Keating K, Fukao T, Loeffler H, Kondo N, Rodemann HP, &, Lavin MF, (2003) Site-directed mutagenesis of the ATM promoter: consequences for response to proliferation and ionizing radiation. Genes Chromosom Cancer 38, 157-167.
131. Lee JS, Galvin KM, &, Shi Y, (1993) Evidence for physical interaction between the zinc-finger transcription factors YY1 and Sp1. Proc Natl Acad Sci USA 90, 6145-6149.
132. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, &, Trojanowska M, (2001) Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 276, 20839-20848.
133. Lim K, &, Chang HI, (2010) O-GlcNAc inhibits interaction between Sp1 and sterol regulatory element binding protein 2. Biochem Biophys Res Commun 393, 314-318.
134. Yieh L, Sanchez HB, &, Osborne TF, (1995) Domains of transcription factor Sp1 required for synergistic activation with sterol regulatory element binding protein 1 of low density lipoprotein receptor promoter. Proc Natl Acad Sci USA 92, 6102-6106.
135. Moustakas A, &, Kardassis D, (1998) Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc Natl Acad Sci USA 95, 6733-6738.
136. Feng XH, Lin X, &, Derynck R, (2000) Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J 19, 5178-5193.
137. Wang CH, Chang HC, &, Hung WC, (2006) p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription. J Cell Physiol 208, 246-252.
138. Wei M, Liu B, Gu Q, Su L, Yu Y, &, Zhu Z, (2013) Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1). Cell Oncol 36, 79-93.
139. Lee JA, Suh DC, Kang JE, Kim MH, Park H, Lee MN, Kim JM, Jeon BN, Roh HE, Yu MY, et al,. (2005) Transcriptional activity of Sp1 is regulated by molecular interactions between the zinc finger DNA binding domain and the inhibitory domain with corepressors, and this interaction is modulated by MEK. J Biol Chem 280, 28061-28071.
140. Han JA, &, Park SC, (2000) Transglutaminase-dependent modulation of transcription factor Sp1 activity. Mol Cells 10, 612-618.
141. Tatsukawa H, Fukaya Y, Frampton G, Martinez-Fuentes A, Suzuki K, Kuo TF, Nagatsuma K, Shimokado K, Okuno M, Wu J, et al,. (2009) Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1. Gastroenterology 136, 1783-95 e10.
142. Li SH, Cheng AL, Zhou H, Lam S, Rao M, Li H, &, Li XJ, (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22, 1277-1287.
143. Singh AK, Battu A, Mohareer K, Hasnain SE, &, Ehtesham NZ, (2010) Transcription of human resistin gene involves an interaction of Sp1 with peroxisome proliferator-activating receptor gamma (PPARgamma). PLoS One 5, e9912.
144. Jeang KT, Chun R, Lin NH, Gatignol A, Glabe CG, &, Fan H, (1993) In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol 67, 6224-6233.
145. Curtin D, Jenkins S, Farmer N, Anderson AC, Haisenleder DJ, Rissman E, Wilson EM, &, Shupnik MA, (2001) Androgen suppression of GnRH-stimulated rat LHbeta gene transcription occurs through Sp1 sites in the distal GnRH-responsive promoter region. Mol Endocrinol 15, 1906-1917.
146. deGraffenried LA, Hopp TA, Valente AJ, Clark RA, &, Fuqua SA, (2004) Regulation of the estrogen receptor alpha minimal promoter by Sp1, USF-1 and ERalpha. Breast Cancer Res Treat 85, 111-120.
147. Han WD, Si YL, Zhao YL, Li Q, Wu ZQ, Hao HJ, &, Song HJ, (2008) GC-rich promoter elements maximally confers estrogen-induced transactivation of LRP16 gene through ERalpha/Sp1 interaction in MCF-7 cells. J Steroid Biochem Mol Biol 109, 47-56.
148. Kang JH, Tsai-Morris CH, &, Dufau ML, (2011) Complex formation and interactions between transcription factors essential for human prolactin receptor gene transcription. Mol Cell Biol 31, 3208-3222.
149. Khan S, Barhoumi R, Burghardt R, Liu S, Kim K, &, Safe S, (2006) Molecular mechanism of inhibitory aryl hydrocarbon receptor-estrogen receptor/Sp1 cross talk in breast cancer cells. Mol Endocrinol 20, 2199-2214.
150. Kim K, Barhoumi R, Burghardt R, &, Safe S, (2005) Analysis of estrogen receptor alpha-Sp1 interactions in breast cancer cells by fluorescence resonance energy transfer. Mol Endocrinol 19, 843-854.
151. Li D, Mitchell D, Luo J, Yi Z, Cho SG, Guo J, Li X, Ning G, Wu X, &, Liu M, (2007) Estrogen regulates KiSS1 gene expression through estrogen receptor alpha and SP protein complexes. Endocrinology 148, 4821-4828.
152. Panno ML, Mauro L, Marsico S, Bellizzi D, Rizza P, Morelli C, Salerno M, Giordano F, &, Ando S, (2006) Evidence that the mouse insulin receptor substrate-1 belongs to the gene family on which the promoter is activated by estrogen receptor alpha through its interaction with Sp1. J Mol Endocrinol 36, 91-105.
153. Sisci D, Middea E, Morelli C, Lanzino M, Aquila S, Rizza P, Catalano S, Casaburi I, Maggiolini M, &, Ando S, (2010) 17beta-estradiol enhances alpha(5) integrin subunit gene expression through ERalpha-Sp1 interaction and reduces cell motility and invasion of ERalpha-positive breast cancer cells. Breast Cancer Res Treat 124, 63-77.
154. Suzuki A, Sanda N, Miyawaki Y, Fujimori Y, Yamada T, Takagi A, Murate T, Saito H, &, Kojima T, (2010) Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem 285, 13444-13453.
155. Tu CC, Velmurugan BK, Day CH, Kuo WW, Yeh SP, Chen RJ, Liao CR, Chen HY, Tsai FJ, Wu WJ, et al,. (2013) Estrogen receptor-alpha over-expression mediated apoptosis in Hep3B cells by binding with Sp1 proteins. J Mol Endocrinol 51, 203-212.
156. Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, &, Filetti S, (2002) Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer 2, 35.
157. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, &, Xie K, (2003) Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9, 6371-6380.
158. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, &, Lu D, (2008) Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 17, 1648-1652.
159. Guan H, Cai J, Zhang N, Wu J, Yuan J, Li J, &, Li M, (2012) Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome. Int J Cancer 130, 593-601.
160. Wang XB, Peng WQ, Yi ZJ, Zhu SL, &, Gan QH, (2007) Expression and prognostic value of transcriptional factor sp1 in breast cancer. Ai Zheng 26, 996-1000.
161. Seznec J, Silkenstedt B, &, Naumann U, (2011) Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. J Neurooncol 101, 365-377.
162. Sun Y, Giacalone NJ, &, Lu B, (2011) Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma. J Thorac Oncol 6, 8-14.
163. Kim JY, Kim EH, Park SS, Lim JH, Kwon TK, &, Choi KS, (2008) Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation. J Cell Biochem 105, 1386-1398.
164. Chae JI, Cho JH, Lee KA, Choi NJ, Seo KS, Kim SB, Lee SH, &, Shim JH, (2012) Role of transcription factor Sp1 in the quercetin-mediated inhibitory effect on human malignant pleural mesothelioma. Int J Mol Med 30, 835-841.
165. Yuan H, Gong A, &, Young CY, (2005) Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 26, 793-801.
166. Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X, Li Q, Yao J, &, Xie K, (2007) Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res 67, 4878-4885.
167. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, &, Xie K, (2004) Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 10, 4109-4117.
168. Lee KE, Shin JA, Hong IS, Cho NP, &, Cho SD, (2013) Effect of methanol extracts of Cnidium officinale Makino and Capsella bursa-pastoris on the apoptosis of HSC-2 human oral cancer cells. Exp Ther Med 5, 789-792.
169. Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC, Chang WC, &, Hung JJ, (2012) Sp1 expression regulates lung tumor progression. Oncogene 31, 3973-3988.
170. Hanahan D, &, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
171. Hanahan D, &, Weinberg RA, (2000) The hallmarks of cancer. Cell 100, 57-70.
172. Endoh T, Tsuji N, Asanuma K, Yagihashi A, &, Watanabe N, (2005) Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 305, 300-311.
173. Furuya M, Tsuji N, Kobayashi D, &, Watanabe N, (2009) Interaction between survivin and aurora-B kinase plays an important role in survivin-mediated up-regulation of human telomerase reverse transcriptase expression. Int J Oncol 34, 1061-1068.
174. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, &, Inoue M, (2000) Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28, 669-677.
175. Liu C, Fang X, Ge Z, Jalink M, Kyo S, Bjorkholm M, Gruber A, Sjoberg J, &, Xu D, (2007) The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res 67, 2626-2631.
176. Marconett CN, Sundar SN, Tseng M, Tin AS, Tran KQ, Mahuron KM, Bjeldanes LF, &, Firestone GL, (2011) Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells. Carcinogenesis 32, 1315-1323.
177. Oh ST, Kyo S, &, Laimins LA, (2001) Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J Virol 75, 5559-5566.
178. Palumbo SL, Ebbinghaus SW, &, Hurley LH, (2009) Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands. J Am Chem Soc 131, 10878-10891.
179. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, &, Inoue M, (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59, 551-557.
180. Wick M, Zubov D, &, Hagen G, (1999) Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 232, 97-106.
181. Zhao JQ, Glasspool RM, Hoare SF, Bilsland A, Szatmari I, &, Keith WN, (2000) Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3. Neoplasia 2, 531-539.
182. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al,. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602.
183. Knappskog S, &, Lonning PE, (2011) Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription 2, 207-210.
184. Knappskog S, &, Lonning PE, (2011) MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget 2, 251-258.
185. Knappskog S, Bjornslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, et al,. (2011) The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell 19, 273-282.
186. Schutte M, Elstrodt F, Bralten LB, Nagel JH, Duijm E, Hollestelle A, Vuerhard MJ, Wasielewski M, Peeters JK, van der Spek P, et al,. (2008) Exon expression arrays as a tool to identify new cancer genes. PLoS One 3, e3007.
187. Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, &, Papa MZ, (2008) MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 111, 497-504.
188. Wang X, Pan L, Feng Y, Wang Y, Han Q, Han L, Han S, Guo J, Huang B, &, Lu J, (2008) P300 plays a role in p16(INK4a) expression and cell cycle arrest. Oncogene 27, 1894-1904.
189. Wang X, Feng Y, Pan L, Wang Y, Xu X, Lu J, &, Huang B, (2007) The proximal GC-rich region of p16(INK4a) gene promoter plays a role in its transcriptional regulation. Mol Cell Biochem 301, 259-266.
190. Wu J, Xue L, Weng M, Sun Y, Zhang Z, Wang W, &, Tong T, (2007) Sp1 is essential for p16 expression in human diploid fibroblasts during senescence. PLoS One 2, e164.
191. Xu W, Zhu Q, Wu Z, Guo H, Wu F, Mashausi DS, Zheng C, &, Li D, (2012) A novel evolutionarily conserved element is a general transcriptional repressor of p21WAF(1)/CIP(1). Cancer Res 72, 6236-6246.
192. Biggs JR, Kudlow JE, &, Kraft AS, (1996) The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem 271, 901-906.
193. Koutsodontis G, Moustakas A, &, Kardassis D, (2002) The role of Sp1 family members, the proximal GC-rich motifs, and the upstream enhancer region in the regulation of the human cell cycle inhibitor p21WAF-1/Cip1 gene promoter. Biochemistry 41, 12771-12784.
194. Kavurma MM, &, Khachigian LM, (2004) Vascular smooth muscle cell-specific regulation of cyclin-dependent kinase inhibitor p21(WAF1/Cip1) transcription by Sp1 is mediated via distinct cis-acting positive and negative regulatory elements in the proximal p21(WAF1/Cip1) promoter. J Cell Biochem 93, 904-916.
195. Werner H, Stannard B, Bach MA, LeRoith D, &, Roberts CT Jr, (1990) Cloning and characterization of the proximal promoter region of the rat insulin-like growth factor I (IGF-I) receptor gene. Biochem Biophys Res Commun 169, 1021-1027.
196. Jensen DE, Rich CB, Terpstra AJ, Farmer SR, &, Foster JA, (1995) Transcriptional regulation of the elastin gene by insulin-like growth factor-I involves disruption of Sp1 binding. Evidence for the role of Rb in mediating Sp1 binding in aortic smooth muscle cells. J Biol Chem 270, 6555-6563.
197. Kaytor EN, Zhu JL, Pao CI, &, Phillips LS, (2001) Physiological concentrations of insulin promote binding of nuclear proteins to the insulin-like growth factor I gene. Endocrinology 142, 1041-1049.
198. Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H, &, Papa MZ, (2006) Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol 191, 605-612.
199. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, &, Werner H, (2007) Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett 257, 236-243.
200. Maor SB, Abramovitch S, Erdos MR, Brody LC, &, Werner H, (2000) BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Genet Metab 69, 130-136.
201. Shahrabani-Gargir L, Pandita TK, &, Werner H, (2004) Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology 145, 5679-5687.
202. Haley J, Whittle N, Bennet P, Kinchington D, Ullrich A, &, Waterfield M, (1987) The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res 1, 375-396.
203. Johnson AC, Ishii S, Jinno Y, Pastan I, &, Merlino GT, (1988) Epidermal growth factor receptor gene promoter. Deletion analysis and identification of nuclear protein binding sites. J Biol Chem 263, 5693-5699.
204. Kageyama R, Merlino GT, &, Pastan I, (1988) Epidermal growth factor (EGF) receptor gene transcription. Requirement for Sp1 and an EGF receptor-specific factor. J Biol Chem 263, 6329-6336.
205. Kitadai Y, Yasui W, Yokozaki H, Kuniyasu H, Haruma K, Kajiyama G, &, Tahara E, (1992) The level of a transcription factor Sp1 is correlated with the expression of EGF receptor in human gastric carcinomas. Biochem Biophys Res Commun 189, 1342-1348.
206. Salvatori L, Pallante P, Ravenna L, Chinzari P, Frati L, Russo MA, &, Petrangeli E, (2003) Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER alpha and beta subtypes via an Sp1 site. Oncogene 22, 4875-4881.
207. Carpentier C, Laigle-Donadey F, Marie Y, Auger N, Benouaich-Amiel A, Lejeune J, Kaloshi G, Delattre JY, Thillet J, &, Sanson M, (2006) Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology 67, 872-874.
208. Pascall JC, &, Brown KD, (1997) Identification of a minimal promoter element of the mouse epidermal growth factor gene. Biochem J 324 (Pt 3), 869-875.
209. Tiesman J, &, Rizzino A, (1990) Nucleotide sequence of the 5′-flanking region of the mouse k-FGF oncogene exhibits an alternating purine:pyrimidine motif with the potential to form Z-DNA. Gene 96, 311-312.
210. Luster TA, Johnson LR, Nowling TK, Lamb KA, Philipsen S, &, Rizzino A, (2000) Effects of three Sp1 motifs on the transcription of the FGF-4 gene. Mol Reprod Dev 57, 4-15.
211. Payson RA, Chotani MA, &, Chiu IM, (1998) Regulation of a promoter of the fibroblast growth factor 1 gene in prostate and breast cancer cells. J Steroid Biochem Mol Biol 66, 93-103.
212. Jimenez SK, Sheikh F, Jin Y, Detillieux KA, Dhaliwal J, Kardami E, &, Cattini PA, (2004) Transcriptional regulation of FGF-2 gene expression in cardiac myocytes. Cardiovasc Res 62, 548-557.
213. Zhu JL, Kaytor EN, Pao CI, Meng XP, &, Phillips LS, (2000) Involvement of Sp1 in the transcriptional regulation of the rat insulin-like growth factor-1 gene. Mol Cell Endocrinol 164, 205-218.
214. Cadoret A, Baron-Delage S, Bertrand F, Kornprost M, Groyer A, Gespach C, Capeau J, &, Cherqui G, (1998) Oncogene-induced up-regulation of Caco-2 cell proliferation involves IGF-II gene activation through a protein kinase C-mediated pathway. Oncogene 17, 877-887.
215. Hyun SW, Kim SJ, Park K, Rho HM, &, Lee YI, (1993) Characterization of the P4 promoter region of the human insulin-like growth factor II gene. FEBS Lett 332, 153-158.
216. Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S, &, Xie K, (2004) A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis 21, 755-764.
217. Lee YI, Lee S, Lee Y, Bong YS, Hyun SW, Yoo YD, Kim SJ, Kim YW, &, Poo HR, (1998) The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4. Oncogene 16, 2367-2380.
218. Li T, Chen YH, Liu TJ, Jia J, Hampson S, Shan YX, Kibler D, &, Wang PH, (2003) Using DNA microarray to identify Sp1 as a transcriptional regulatory element of insulin-like growth factor 1 in cardiac muscle cells. Circ Res 93, 1202-1209.
219. Asanuma K, Tsuji N, Endoh T, Yagihashi A, &, Watanabe N, (2004) Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J Immunol 172, 3922-3929.
220. Kim YH, Lee DH, Jeong JH, Guo ZS, &, Lee YJ, (2008) Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol 75, 1946-1958.
221. Lee KA, Lee YJ, Ban JO, Lee YJ, Lee SH, Cho MK, Nam HS, Hong JT, &, Shim JH, (2012) The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1. Int J Mol Med 30, 21-27.
222. Lee SO, Abdelrahim M, Yoon K, Chintharlapalli S, Papineni S, Kim K, Wang H, &, Safe S, (2010) Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Res 70, 6824-6836.
223. Li F, &, Altieri DC, (1999) Transcriptional analysis of human survivin gene expression. Biochem J 344 (Pt 2), 305-311.
224. Li F, &, Altieri DC, (1999) The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 59, 3143-3151.
225. Kim YH, Park JW, Lee JY, &, Kwon TK, (2004) Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 25, 1813-1820.
226. Yoshida T, Maeda A, Tani N, &, Sakai T, (2001) Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett 507, 381-385.
227. Duan H, Heckman CA, &, Boxer LM, (2005) Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25, 1608-1619.
228. Azahri NS, Di Bartolo BA, Khachigian LM, &, Kavurma MM, (2012) Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration. J Cell Biochem 113, 2597-2606.
229. Lee KA, Chae JI, &, Shim JH, (2012) Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma. J Biomed Sci 19, 60.
230. Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS, &, Kwon TK, (2006) Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 5, 2737-2746.
231. Kavurma MM, Bobryshev Y, &, Khachigian LM, (2002) Ets-1 positively regulates Fas ligand transcription via cooperative interactions with Sp1. J Biol Chem 277, 36244-36252.
232. Kavurma MM, Santiago FS, Bonfoco E, &, Khachigian LM, (2001) Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem 276, 4964-4971.
233. Savickiene J, Treigyte G, Magnusson KE, &, Navakauskiene R, (2005) p21 (Waf1/Cip1) and FasL gene activation via Sp1 and NFkappaB is required for leukemia cell survival but not for cell death induced by diverse stimuli. Int J Biochem Cell Biol 37, 784-796.
234. Abdelrahim M, &, Safe S, (2005) Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 68, 317-329.
235. Abdelrahim M, Smith R III, Burghardt R, &, Safe S, (2004) Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 64, 6740-6749.
236. Eisermann K, Broderick CJ, Bazarov A, Moazam MM, &, Fraizer GC, (2013) Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol Cancer 12, 7.
237. Finkenzeller G, Sparacio A, Technau A, Marme D, &, Siemeister G, (1997) Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15, 669-676.
238. Kazi AA, Jones JM, &, Koos RD, (2005) Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. Mol Endocrinol 19, 2006-2019.
239. Koos RD, Kazi AA, Roberson MS, &, Jones JM, (2005) New insight into the transcriptional regulation of vascular endothelial growth factor expression in the endometrium by estrogen and relaxin. Ann N Y Acad Sci 1041, 233-247.
240. Milanini J, Vinals F, Pouyssegur J, &, Pages G, (1998) p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 273, 18165-18172.
241. Motoyama K, Fukumoto S, Koyama H, Emoto M, Shimano H, Maemura K, &, Nishizawa Y, (2006) SREBP inhibits VEGF expression in human smooth muscle cells. Biochem Biophys Res Commun 342, 354-360.
242. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, &, Sukhatme VP, (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17, 5629-5639.
243. Pages G, &, Pouyssegur J, (2005) Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc Res 65, 564-573.
244. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, Stokoe D, Milanini-Mongiat J, Pages G, O'Rourke DM, Bernhard E, et al,. (2004) Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 15, 4841-4853.
245. Reisinger K, Kaufmann R, &, Gille J, (2003) Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. J Cell Sci 116, 225-238.
246. Santra M, Santra S, Zhang J, &, Chopp M, (2008) Ectopic decorin expression up-regulates VEGF expression in mouse cerebral endothelial cells via activation of the transcription factors Sp1, HIF1alpha, and Stat3. J Neurochem 105, 324-337.
247. Schafer G, Cramer T, Suske G, Kemmner W, Wiedenmann B, &, Hocker M, (2003) Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem 278, 8190-8198.
248. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC, &, Xie K, (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61, 4143-4154.
249. Stoner M, Wormke M, Saville B, Samudio I, Qin C, Abdelrahim M, &, Safe S, (2004) Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins. Oncogene 23, 1052-1063.
250. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, &, Abraham JA, (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266, 11947-11954.
251. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, &, Xie K, (2004) Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64, 2030-2038.
252. Yu DC, Waby JS, Chirakkal H, Staton CA, &, Corfe BM, (2010) Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. Mol Cancer 9, 276.
253. Okamoto M, Ono M, Uchiumi T, Ueno H, Kohno K, Sugimachi K, &, Kuwano M, (2002) Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells-transcriptional activation and messenger RNA stabilization. Biochim Biophys Acta 1574, 24-34.
254. Liu MY, Eyries M, Zhang C, Santiago FS, &, Khachigian LM, (2006) Inducible platelet-derived growth factor D-chain expression by angiotensin II and hydrogen peroxide involves transcriptional regulation by Ets-1 and Sp1. Blood 107, 2322-2329.
255. Rafty LA, &, Khachigian LM, (2001) Sp1 phosphorylation regulates inducible expression of platelet-derived growth factor B-chain gene via atypical protein kinase C-zeta. Nucleic Acids Res 29, 1027-1033.
256. Rafty LA, Santiago FS, &, Khachigian LM, (2002) NF1/X represses PDGF A-chain transcription by interacting with Sp1 and antagonizing Sp1 occupancy of the promoter. EMBO J 21, 334-343.
257. Santiago FS, &, Khachigian LM, (2004) Ets-1 stimulates platelet-derived growth factor A-chain gene transcription and vascular smooth muscle cell growth via cooperative interactions with Sp1. Circ Res 95, 479-487.
258. Belaguli NS, Aftab M, Rigi M, Zhang M, Albo D, &, Berger DH, (2010) GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression. Neoplasia 12, 856-865.
259. Benasciutti E, Pages G, Kenzior O, Folk W, Blasi F, &, Crippa MP, (2004) MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 104, 256-262.
260. Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, &, Salvatore M, (2000) Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 60, 1546-1551.
261. Hockings JK, Degner SC, Morgan SS, Kemp MQ, &, Romagnolo DF, (2008) Involvement of a specificity proteins-binding element in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene. Breast Cancer Res 10, R29.
262. Maor S, Papa MZ, Yarden RI, Friedman E, Lerenthal Y, Lee SW, Mayer D, &, Werner H, (2007) Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. Horm Metab Res 39, 179-185.
263. Keating KE, Gueven N, Watters D, Rodemann HP, &, Lavin MF, (2001) Transcriptional downregulation of ATM by EGF is defective in ataxia-telangiectasia cells expressing mutant protein. Oncogene 20, 4281-4290.
264. Truman JP, Gueven N, Lavin M, Leibel S, Kolesnick R, Fuks Z, &, Haimovitz-Friedman A, (2005) Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. J Biol Chem 280, 23262-23272.
265. Bu Y, Suenaga Y, Ono S, Koda T, Song F, Nakagawara A, &, Ozaki T, (2008) Sp1-mediated transcriptional regulation of NFBD1/MDC1 plays a critical role in DNA damage response pathway. Genes Cells 13, 53-66.
266. Dalvai M, Mondesert O, Bourdon JC, Ducommun B, &, Dozier C, (2011) Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors. Oncogene 30, 2282-2288.
267. Dalvai M, Mondesert O, Bugler B, Manenti S, Ducommun B, &, Dozier C, (2012) Doxorubicin promotes transcriptional upregulation of Cdc25B in cancer cells by releasing Sp1 from the promoter. Oncogene 32, 5123-5128.
268. Sengupta S, Shimamoto A, Koshiji M, Pedeux R, Rusin M, Spillare EA, Shen JC, Huang LE, Lindor NM, Furuichi Y, et al,. (2005) Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene 24, 1738-1748.
269. Oei SL, Herzog H, Hirsch-Kauffmann M, Schneider R, Auer B, &, Schweiger M, (1994) Transcriptional regulation and autoregulation of the human gene for ADP-ribosyltransferase. Mol Cell Biochem 138, 99-104.
270. Laniel MA, Poirier GG, &, Guerin SL, (2004) A conserved initiator element on the mammalian poly(ADP-ribose) polymerase-1 promoters, in combination with flanking core elements, is necessary to obtain high transcriptional activity. Biochim Biophys Acta 1679, 37-46.
271. Hao B, Miao X, Li Y, Zhang X, Sun T, Liang G, Zhao Y, Zhou Y, Wang H, Chen X, et al,. (2006) A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene 25, 3613-3620.
272. Zhou ZQ, &, Walter CA, (1998) Cloning and characterization of the promoter of baboon XRCC1, a gene involved in DNA strand-break repair. Somat Cell Mol Genet 24, 23-39.
273. Iso T, Futami K, Iwamoto T, &, Furuichi Y, (2007) Modulation of the expression of bloom helicase by estrogenic agents. Biol Pharm Bull 30, 266-271.
274. Wang H, Wang S, Shen L, Chen Y, Zhang X, Zhou J, Wang Z, Hu C, Yue W, &, Wang H, (2010) Chk2 down-regulation by promoter hypermethylation in human bulk gliomas. Life Sci 86, 185-191.
275. Zhang S, Lu J, Zhao X, Wu W, Wang H, Lu J, Wu Q, Chen X, Fan W, Chen H, et al,. (2010) A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer. Carcinogenesis 31, 1251-1258.
276. Xu XS, Wang L, Abrams J, &, Wang G, (2011) Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. J Hematol Oncol 4, 17.
277. Jaitovich-Groisman I, Benlimame N, Slagle BL, Perez MH, Alpert L, Song DJ, Fotouhi-Ardakani N, Galipeau J, &, Alaoui-Jamali MA, (2001) Transcriptional regulation of the TFIIH transcription repair components XPB and XPD by the hepatitis B virus x protein in liver cells and transgenic liver tissue. J Biol Chem 276, 14124-14132.
278. Ma L, Weeda G, Jochemsen AG, Bootsma D, Hoeijmakers JH, &, van der Eb AJ, (1992) Molecular and functional analysis of the XPBC/ERCC-3 promoter: transcription activity is dependent on the integrity of an Sp1-binding site. Nucleic Acids Res 20, 217-224.
279. Nichols AF, Itoh T, Zolezzi F, Hutsell S, &, Linn S, (2003) Basal transcriptional regulation of human damage-specific DNA-binding protein genes DDB1 and DDB2 by Sp1, E2F, N-myc and NF1 elements. Nucleic Acids Res 31, 562-569.
280. Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, Nagawa H, &, Suzuki N, (2004) Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol 25, 461-468.
281. Wang S, Wang M, Yin S, Fu G, Li C, Chen R, Li A, Zhou J, Zhang Z, &, Liu Q, (2008) A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer. Mutat Res 638, 26-36.
282. Lin Z, Zhang X, Tuo J, Guo Y, Green B, Chan CC, Tan W, Huang Y, Ling W, Kadlubar FF, et al,. (2008) A variant of the Cockayne syndrome B gene ERCC6 confers risk of lung cancer. Hum Mutat 29, 113-122.
283. Yamabe Y, Shimamoto A, Goto M, Yokota J, Sugawara M, &, Furuichi Y, (1998) Sp1-mediated transcription of the Werner helicase gene is modulated by Rb and p53. Mol Cell Biol 18, 6191-6200.
284. Hung WC, Tseng WL, Shiea J, &, Chang HC, (2010) Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett 288, 156-161.
285. Sroka IC, Nagle RB, &, Bowden GT, (2007) Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia 9, 406-417.
286. Yun S, Dardik A, Haga M, Yamashita A, Yamaguchi S, Koh Y, Madri JA, &, Sumpio BE, (2002) Transcription factor Sp1 phosphorylation induced by shear stress inhibits membrane type 1-matrix metalloproteinase expression in endothelium. J Biol Chem 277, 34808-34814.
287. Chang HC, Liu LT, &, Hung WC, (2004) Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cell Signal 16, 675-679.
288. Sasahara RM, Takahashi C, &, Noda M, (1999) Involvement of the Sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. Biochem Biophys Res Commun 264, 668-675.
289. Sasahara RM, Takahashi C, Sogayar MC, &, Noda M, (1999) Oncogene-mediated downregulation of RECK, a novel transformation suppressor gene. Braz J Med Biol Res 32, 891-895.
290. Apt D, Watts RM, Suske G, &, Bernard HU, (1996) High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transformation correlate with the activation of the HPV-16 promoter. Virology 224, 281-291.
291. D'Costa ZJ, Jolly C, Androphy EJ, Mercer A, Matthews CM, &, Hibma MH, (2012) Transcriptional repression of E-cadherin by human papillomavirus type 16 E6. PLoS One 7, e48954.
292. Faraldo ML, Rodrigo I, Behrens J, Birchmeier W, &, Cano A, (1997) Analysis of the E-cadherin and P-cadherin promoters in murine keratinocyte cell lines from different stages of mouse skin carcinogenesis. Mol Carcinog 20, 33-47.
293. Graff JR, Herman JG, Myohanen S, Baylin SB, &, Vertino PM, (1997) Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 272, 22322-22329.
294. Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, &, Chen JH, (2005) Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 24, 8277-8290.
295. Han S, &, Roman J, (2005) COX-2 inhibitors suppress integrin alpha5 expression in human lung carcinoma cells through activation of Erk: involvement of Sp1 and AP-1 sites. Int J Cancer 116, 536-546.
296. Nam EH, Lee Y, Park YK, Lee JW, &, Kim S, (2012) ZEB2 upregulates integrin alpha5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells. Carcinogenesis 33, 563-571.
297. Kuo L, Chang HC, Leu TH, Maa MC, &, Hung WC, (2006) Src oncogene activates MMP-2 expression via the ERK/Sp1 pathway. J Cell Physiol 207, 729-734.
298. Pan MR, &, Hung WC, (2002) Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 277, 32775-32780.
299. Qin H, Sun Y, &, Benveniste EN, (1999) The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 274, 29130-29137.
300. Pollak M, (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12, 159-169.
301. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, &, Macaulay VM, (2008) The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14, 6364-6370.
302. Kaytor EN, Zhu JL, Pao CI, &, Phillips LS, (2001) Insulin-responsive nuclear proteins facilitate Sp1 interactions with the insulin-like growth factor-I gene. J Biol Chem 276, 36896-36901.
303. Mitsudomi T, &, Yatabe Y, (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277, 301-308.
304. Li J, Zou WX, &, Chang KS, (2014) Inhibition of Sp1 Functions by Its Sequestration into PML Nuclear Bodies. PLoS One 9, e94450.
305. Martínez-Balbás MA, Dey A, Rabindran SK, Ozato K, &, Wu C, (1995) Displacement of sequence-specific transcription factors from mitotic chromatin. Cell 83, 29-38.
306. Jin W, Chen BB, Li JY, Zhu H, Huang M, Gu SM, Wang QQ, Chen JY, Yu S, Wu J, et al,. (2012) TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Mol Cell Biol 32, 50-63.
307. Salvatori L, Ravenna L, Caporuscio F, Principessa L, Coroniti G, Frati L, Russo MA, &, Petrangeli E, (2011) Action of retinoic acid receptor on EGFR gene transactivation and breast cancer cell proliferation: interplay with the estrogen receptor. Biomed Pharmacother 65, 307-312.
308. Salvatori L, Ravenna L, Felli MP, Cardillo MR, Russo MA, Frati L, Gulino A, &, Petrangeli E, (2000) Identification of an estrogen-mediated deoxyribonucleic acid-binding independent transactivation pathway on the epidermal growth factor receptor gene promoter. Endocrinology 141, 2266-2274.
309. Koutsodontis G, Vasilaki E, Chou WC, Papakosta P, &, Kardassis D, (2005) Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem J 389, 443-455.
310. Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS, Chen CY, Lu YY, Tang YA, Yang YC, Yang PC, et al,. (2010) Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 70, 5807-5817.
311. Pietrzak M, &, Puzianowska-Kuznicka M, (2008) p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter. Biol Chem 389, 383-393.
312. Krekac D, Brozkova K, Knoflickova D, Hrstka R, Muller P, Nenutil R, &, Vojtesek B, (2008) MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology 74, 84-87.
313. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr, &, Ratain MJ, (2005) A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 65, 46-53.
314. Rayess H, Wang MB, &, Srivatsan ES, (2012) Cellular senescence and tumor suppressor gene p16. Int J Cancer 130, 1715-1725.
315. Esteller M, Corn PG, Baylin SB, &, Herman JG, (2001) A gene hypermethylation profile of human cancer. Cancer Res 61, 3225-3229.
316. Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, Lleonart ME, Castellvi J, &, Ramon y Cajal S, (2011) p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 30, 2087-2097.
317. Oh JE, Han JA, &, Hwang ES, (2007) Downregulation of transcription factor, Sp1, during cellular senescence. Biochem Biophys Res Commun 353, 86-91.
318. Zhao J, Bilsland A, Hoare SF, &, Keith WN, (2003) Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene. FEBS Lett 536, 111-119.
319. Roder K, Wolf SS, Larkin KJ, &, Schweizer M, (1999) Interaction between the two ubiquitously expressed transcription factors NF-Y and Sp1. Gene 234, 61-69.
320. Liu L, Ishihara K, Ichimura T, Fujita N, Hino S, Tomita S, Watanabe S, Saitoh N, Ito T, &, Nakao M, (2009) MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity. J Biol Chem 284, 5165-5174.
321. Athanasoula K, Gogas H, Polonifi K, Vaiopoulos AG, Polyzos A, &, Mantzourani M, (2014) Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Lett 347, 175-182.
322. Knight JS, Cotter MA II, &, Robertson ES, (2001) The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter. J Biol Chem 276, 22971-22978.
323. Bochman ML, Paeschke K, &, Zakian VA, (2012) DNA secondary structures: stability and function of G-quadruplex structures. Nat Rev Genet 13, 770-780.
324. Todd AK, &, Neidle S, (2008) The relationship of potential G-quadruplex sequences in cis-upstream regions of the human genome to SP1-binding elements. Nucleic Acids Res 36, 2700-2704.
325. Kumar P, Yadav VK, Baral A, Kumar P, Saha D, &, Chowdhury S, (2011) Zinc-finger transcription factors are associated with guanine quadruplex motifs in human, chimpanzee, mouse and rat promoters genome-wide. Nucleic Acids Res 39, 8005-8016.
326. Raiber EA, Kranaster R, Lam E, Nikan M, &, Balasubramanian S, (2012) A non-canonical DNA structure is a binding motif for the transcription factor SP1 in vitro. Nucleic Acids Res 40, 1499-1508.
327. Cazzalinia O, Scovassib AI, Savioa M, Stivalaa LA, &, Prosperi E, (2010) Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response. Mutation Res 704, 12-20.
328. Abbas T, &, Dutta A, (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9, 400-414.
329. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, &, Jacks T, (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9, 935-944.
330. Owen GI, Richer JK, Tung L, Takimoto G, &, Horwitz KB, (1998) Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 273, 10696-10701.
331. Wei Z, Jiang X, Qiao H, Zhai B, Zhang L, Zhang Q, Wu Y, Jiang H, &, Sun X, (2013) STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal 25, 931-938.
332. Pagliuca A, Gallo P, &, Lania L, (2000) Differential role for Sp1/Sp3 transcription factors in the regulation of the promoter activity of multiple cyclin-dependent kinase inhibitor genes. J Cell Biochem 76, 360-367.
333. Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C, &, Otterson GA, (2003) Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol 23, 4056-4065.
334. Ganapathy M, Ghosh R, Jianping X, Zhang X, Bedolla R, Schoolfield J, Yeh IT, Troyer DA, Olumi AF, &, Kumar AP, (2009) Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res 15, 1601-1611.
335. Ulrich E, Kauffmann-Zeh A, Hueber AO, Williamson J, Chittenden T, Ma A, &, Evan G, (1997) Gene structure, cDNA sequence, and expression of murine Bak, a proapoptotic Bcl-2 family member. Genomics 44, 195-200.
336. Maksimovic-Ivanic D, Stosic-Grujicic S, Nicoletti F, &, Mijatovic S, (2012) Resistance to TRAIL and how to surmount it. Immunol Res 52, 157-168.
337. French LE, &, Tschopp J, (2002) Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol 12, 51-55.
338. Athanasoula K, Gogas H, Polonifi K, Vaiopoulos AG, Polyzos A, &, Mantzourani M, (2014) Survivin beyond physiology: Orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Letters 347, 175-182.
339. Xu R, Zhang P, Huang J, Ge S, Lu J, &, Qian G, (2007) Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 356, 286-292.
340. Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T, &, Li F, (2005) Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem 280, 9745-9751.
341. Billon N, Carlisi D, Datto MB, van Grunsven LA, Watt A, Wang XF, &, Rudkin BB, (1999) Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/CIP1 during NGF-mediated neuronal differentiation. Oncogene 18, 2872-2882.
342. Xiao H, Hasegawa T, &, Isobe K, (2000) p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 275, 1371-1376.
343. Ramos YF, Hestand MS, Verlaan M, Krabbendam E, Ariyurek Y, van Galen M, van Dam H, van Ommen GJ, den Dunnen JT, Zantema A, et al,. (2010) Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res 38, 5396-5408.
344. Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG, &, Li F, (2012) Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 3, 179-197.
345. Trisciuoglio D, Iervolino A, Candiloro A, Fibbi G, Fanciulli M, Zangemeister-Wittke U, Zupi G, &, Del Bufalo D, (2004) bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity. J Biol Chem 279, 6737-6745.
346. Shibuya M, (2013) Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 153, 13-19.
347. Kieran MW, Kalluri R, &, Cho YJ, (2012) The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med 2, a006593.
348. Donovan K, Alekseev O, Qi X, Cho W, &, Azizkhan-Clifford J, (2014) O-GlcNAc modification of transcription factor Sp1 mediates hyperglycemia-induced VEGF-A upregulation in retinal cells. Invest Ophthalmol Vis Sci 91 (s252).
349. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, &, Reginato MJ, (2012) Critical role of O-Linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem 287, 11070-11081.
350. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, Vosseller K, &, Reginato MJ, (2010) Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene 29, 2831-2842.
351. Issad T, Masson E, &, Pagesy P, (2010) O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab 36, 423-435.
352. Hart GW, Slawson C, Ramirez-Correa G, &, Lagerlof O, (2011) Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem 80, 825-858.
353. Wang SS, Chen LW, Chen LY, Tsai HH, Shih YC, Yang CT, &, Chang PJ, (2010) Transcriptional regulation of the ORF61 and ORF60 genes of Kaposi's sarcoma-associated herpesvirus. Virology 397, 311-321.
354. Haas TL, Stitelman D, Davis SJ, Apte SS, &, Madri JA, (1999) Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem 274, 22679-22685.
355. Carneiro P, Fernandes MS, Figueiredo J, Caldeira J, Carvalho J, Pinheiro H, Leite M, Melo S, Oliveira P, Simoes-Correia J, et al,. (2012) E-cadherin dysfunction in gastric cancer-cellular consequences, clinical applications and open questions. FEBS Lett 586, 2981-2989.
356. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa AM, Simoes-Correia J, Oliveira MJ, et al,. (2012) Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta 1826, 297-311.
357. David JM, &, Rajasekaran AK, (2012) Dishonorable discharge: the oncogenic roles of cleaved E-cadherin fragments. Cancer Res 72, 2917-2923.
358. Banine F, Bartlett C, Gunawardena R, Muchard C, Yaniv M, Knudsen ES, Weissman BE, &, Sherman LS, (2005) SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res 65, 3542-3547.
359. Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, Holloway RW, Kaja S, &, Abdelrahim M, (2011) Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 122, 163-170.
360. Pathi S, Jutooru I, Chadalapaka G, Nair V, Lee SO, &, Safe S, (2012) Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (Sp) transcription factors. PLoS One 7, e48208.
361. Pathi S, Li X, &, Safe S, (2013) Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors. Mol Carcinog 53 (Suppl 1), E53-E61.
362. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, &, Bigler J, (2005) PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14, 616-619.
363. Lian S, Potula HH, Pillai MR, Van Stry M, Koyanagi M, Chung L, Watanabe M, &, Bix M, (2013) Transcriptional activation of mina by sp1/3 factors. PLoS One 8, e80638.
364. Yu J, Wei M, Boyd Z, Lehmann EB, Trotta R, Mao H, Liu S, Becknell B, Jaung MS, Jarjoura D, et al,. (2007) Transcriptional control of human T-BET expression: the role of Sp1. Eur J Immunol 37, 2549-2561.
365. Kim SH, Shanware NP, Bowler MJ, &, Tibbetts RS, (2010) Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. J Biol Chem 285, 34097-34105.
366. Laskow TC, Buchser WJ, Pitt BR, Basse PH, Butterfield LH, Kalinski P, &, Lotze MT, (2010) Zinc in innate and adaptive tumor immunity. J Transl Med 8, 118.
367. Astrinidis A, Kim J, Kelly CM, Olofsson BA, Torabi B, Sorokina EM, &, Azizkhan-Clifford J, (2010) The transcription factor SP1 regulates centriole function and chromosomal stability through a functional interaction with the mammalian target of rapamycin/raptor complex. Genes Chromosom Cancer 49, 282-297.
368. Jensen DE, Black AR, Swick AG, &, Azizkhan JC, (1997) Distinct roles for Sp1 and E2F sites in the growth/cell cycle regulation of the DHFR promoter. J Cell Biochem 67, 24-31.
369. Black AR, Jensen D, Lin SY, &, Azizkhan JC, (1999) Growth/cell cycle regulation of Sp1 phosphorylation. J Biol Chem 274, 1207-1215.
370. Gueven N, Fukao T, Luff J, Paterson C, Kay G, Kondo N, &, Lavin MF, (2006) Regulation of the Atm promoter in vivo. Genes Chromosom Cancer 45, 61-71.
371. Gardiner-Garden M, &, Frommer M, (1987) CpG islands in vertebrate genomes. J Mol Biol 196, 261-282.
372. Jiang Y, Liu S, Chen X, Cao Y, &, Tao Y, (2013) Genome-wide distribution of DNA methylation and DNA demethylation and related chromatin regulators in cancer. Biochim Biophys Acta 1835, 155-163.
373. Brandeis M, Frank D, Keshet I, Siegfried Z, Mendelsohn M, Nemes A, Temper V, Razin A, &, Cedar H, (1994) Sp1 elements protect a CpG island from de novo methylation. Nature 371, 435-438.
374. Siegfried Z, Eden S, Mendelsohn M, Feng X, Tsuberi BZ, &, Cedar H, (1999) DNA methylation represses transcription in vivo. Nat Genet 22, 203-206.
375. Clark SJ, Harrison J, &, Molloy PL, (1997) Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 195, 67-71.
376. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, &, Dammann R, (2005) Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol 25, 3923-3933.
377. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, et al,. (2008) Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 111, 2364-2373.
378. Cruickshanks HA, McBryan T, Nelson DM, Vanderkraats ND, Shah PP, van Tuyn J, Singh Rai T, Brock C, Donahue G, Dunican DS, et al,. (2013) Senescent cells harbour features of the cancer epigenome. Nat Cell Biol 15, 1495-1506.